Ratings GC Biopharma Corp.

Equities

A006280

KR7006280002

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
111,900 ^KRW	+0.72%		+2.57%	-10.84%

Mar. 20	GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company appears to be poorly valued given its net asset value.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company does not generate enough profits, which is an alarming weak point.
The company is in debt and has limited leeway for investment
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 44.63 times its estimated earnings per share for the ongoing year.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
GC BIOPHARMA CORP.	-10.84%	928M	D
ELI LILLY AND COMPANY	+25.83%	661B	C+
NOVO NORDISK A/S	+27.00%	566B	B
JOHNSON & JOHNSON	-6.76%	352B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+3.00%	283B	C+
ASTRAZENECA PLC	+13.09%	231B	B+
NOVARTIS AG	+5.46%	200B	B-
ROCHE HOLDING AG	-9.61%	195B	A+
AMGEN INC.	-6.26%	145B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes